Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

FDA Investigating Eprex Anemia Drug

Posted by Chrissie Cole
Monday, September 29, 2008 1:15 AM EST
Category: Major Medical
Tags: FDA & Prescription Drugs, Anemia, Johnson & Johnson, Eprex, Defective Drugs, Procrit


LEARN MORE

IMAGE SOURCE: © Eprex

The U.S. Food and Drug Administration (FDA) is examining an increased rate of deaths in patients treated with an anemia drug made by Johnson & Johnson in German trials of stroke patients.

The study found 16 percent of patients treated with the drug, Eprex, within six hours of the onset of stroke symptoms died more frequently, compared with nine percent of patients who were given a placebo, federal health officials said in a recent statement.

The results have been reported to the FDA and European regulatory authorities. Additional research is in progress to better understand the preliminary findings.

Eprex, also known as Procrit or Epoetin Alfa, is a drug used to treat anemia. The drugs are part of a class called erythropoiesis-stimulating agents (ESAs), which are approved for treating patients with cancer and kidney disease.

In recent years, the safety of ESAs has come under fire after other studies have found tumor growth and shorter survival rates in some patients given high doses of the drug.

The agency is aware of other current ongoing trials testing the potential neurological effects of Eprex.

The increased death rates in the study “suggests close monitoring of patients in other ongoing trials to observe adverse outcomes and to determine whether or not the potential benefits outweigh the risks for enrolled patients is needed,” said the agency.

Last week, Johnson & Johnson reported that early data showed Eprex patients in the German study died more frequently than patients taking placebo’s and said they are doing additional analysis to better understand the findings.

The company supplied financing and drug supplies, but had no role in the design or conduct of the trial, according to Mark Wolfe, a Johnson & Johnson spokesman. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes